New insights into the pharmacodynamic and pharmacokinetic properties of statins
- 8 December 1999
- journal article
- review article
- Published by Elsevier
- Vol. 84 (3) , 413-428
- https://doi.org/10.1016/s0163-7258(99)00045-5
Abstract
No abstract availableKeywords
This publication has 157 references indexed in Scilit:
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998
- Drug Interactions of Lipid-Altering DrugsDrug Safety, 1998
- Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 1997
- Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophagesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- Effects of Atorvastatin, an HMG‐CoA Reductase Inhibitor, on Hepatic Oxidative Metabolism of AntipyrineThe Journal of Clinical Pharmacology, 1996
- HMG-CoA Reductase Inhibitors Reduce Acetyl LDL Endocytosis in Mouse Peritoneal MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Clinical Pharmacokinetics of PravastatinClinical Pharmacokinetics, 1994
- Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteinsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
- Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal ImpairmentThe Journal of Clinical Pharmacology, 1992
- Regulation of the mevalonate pathwayNature, 1990